OCUP - Ocuphire stock rockets 71% after Phase 2 VEGA-1 trial in presbyopia meets endpoints

Ocuphire Pharma (OCUP) soars 71% premarket after announcing results from Phase 2 VEGA-1 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine ((LDP)) in presbyopic subjects successfully met its primary and many secondary endpoints. Highlights from the VEGA-1 Phase 2 Trial in Presbyopia: 61% of subjects treated with Nyxol + LDP improved 15 letters or greater (? 3 lines) in photopic binocular near vision at 1 hour compared with 28% of subjects on placebo with statistical significance (p = 0.003 with placebo adjusted difference of 33%) Nyxol + LDP met co-primary endpoint vs. placebo gaining 15 letters (3 lines) near vision with less than 5 letters of distance vision loss, rapid onset of efficacy at 30 mins, durable near vision improvement through at least 6 hours and and sustained duration of efficacy.Nyxol + LDP was well tolerated and showed a favorable safety profile.On the strength of these results, Ocuphire plans to move

For further details see:

Ocuphire stock rockets 71% after Phase 2 VEGA-1 trial in presbyopia meets endpoints